Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2016
Pharma News, 2016
FDA Approves Erelzi
August 31, 2016 -- The U.
Drug found to treat rare genetic disorder
In a recent study researchers have discovered a type of drug delivery system that may offer new hope for patients with a rare, ultimately fatal genetic disorder Niemann Pick Type C1 and make what migh...
Israeli Researchers Invent Mind-Controlled DNA Nanobots for Potential Treatment of Brain Disorders From Epilepsy to Depression
Taking a cue from science fiction, Israeli researchers have invented mind-controlled nanobots that have the potential to treat “challenging” brain disorders, the UK’s Daily Mail reported.
Florida finds first local mosquitoes with Zika virus
Florida officials on Thursday said they have trapped the first mosquitoes that tested positive for the Zika virus in the Miami area, further confirming reports of local U.
Infectious diseases point-of-care testing market will rise to over $1.17 billion by 2022, says GlobalData
The infectious diseases point-of-care testing (POCT) market is set to rise from $696.
Novo Nordisk's veteran CEO Lars Rebien Sorensen to step down
Novo Nordisk's long-serving chief executive Lars Rebien Sorensen is to step down early, it was announced on Thursday, at a time when the world's largest insulin maker has said it faces increas...
Forget Apple. It's time to collect from tax-dodging Gilead, tax group urges U.S. Treasury
EU antitrust regulators this week cracked down on Apple, ordering the American tech giant to fork over about $14.
Betagenon AB: Start of Phase IIa Proof-of-Concept Clinical Trial of AMPK Activator O304 in Type 2 Diabetics
STOCKHOLM, Sweden I August 31, 2016 I Betagenon AB/Baltic Bio AB announces the start of Phase IIa proof-of-concept clinical trial of the first-in-class AMPK activator compound O304 in type2 diabetics.
Folic acid: what is it and should we all be taking it?
Folic acid, aka folate or B9, is in the spotlight thanks to a new study which found food fortified with the B vitamin helped to lower rates of congenital heart defects in Canada.
Forensic DNA analysis checks the origin of cultured cells
Cell lines are cultured cells that are commonly used in medical research.
Mylan likely to 'get credit' for new EpiPen generic, but is it too little, too late?
After a week scrabbling to calm the raging EpiPen pricing crisis, culminating with new copay assistance, Mylan on Monday unveiled its latest tactic.
AcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX‑04 in the Emergency Department at the International Society for Burn Injuries
REDWOOD CITY, CA, USA I August 29, 2016 I AcelRx Pharmaceuticals, Inc.
16
17
18
19
20
21
22
23
24
